Stay updated with breaking news from Element Science. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
This randomized trial compares the effect of intermediate-dose vs standard prophylactic enoxaparin on a composite outcome of acute venous thromboembolism (VTE),
Element Science announced positive data from a study of its Jewel patch-wearable cardioverter defibrillator (P-WCD).
Were the GLP-1 receptor agonist drug's apparent benefits in STEP-HFpEF due solely to weight loss or additional mechanisms? The trial offers a clue, experts say.
Bristol Myers Squibb in collaboration with Janssen Pharmaceuticals announced all three prospective antithrombotic indications for milvexian have received fast track designation from the FDA. The designation covers all three phase 3 Librexia development studies of the investigational oral factor XIa inhibitor: Librexia Stroke, Librexia ACS and Librexia AF. According to a company press release, the